Home / Diabetes In Control (page 1330)

Diabetes In Control

LAF237 is the lead DPP-IV inhibitor compound from Novartis.

Preliminary results of 12 week Phase 2 studies show LAF237 was well tolerated and demonstrated surprising glucose-lowering potency both as monotherapy, and in combination with metformin. Novartis is proceeding to Phase 3 Clinical Trials with this compound. See this weeks Item #2. To get slides on how LAF237 works

Read More »

Take Time to Care…About Diabetes

Take Time to Care…About Diabetes… . Print Patient Brochures This exciting new public awareness effort is the result of a partnership between the ADA, the FDA´s Office of Women´s Health and the National Association of Chain Drugstores.

Read More »

10 Reasons Why Adults With Diabetes Should Exercise

1. To increase bone density and prevent osteoporosis. As we live longer, osteoporosis is becoming one of the major health problems associated with old age. It affects some 20 million women and 5 million men and leads to more than 250,000 hip fractures each year. Exercise delays the onset of …

Read More »

Caduet (Pfizer):

The FDA has approved amlodipine combined with atorvastatin calcium, a duel therapy designed to treat both hypertension and hypercholesterolemia simultaneously. It contains amlodipine besylate (Novasc) and atorvastatin (Lipitor)

Read More »